Literature DB >> 10026383

Simple standardised neuropsychological assessments aid in the differential diagnosis of dementia with Lewy bodies from Alzheimer's disease and vascular dementia.

C G Ballard1, G Ayre, J O'Brien, A Sahgal, I G McKeith, P G Ince, R H Perry.   

Abstract

Consecutive patients from a dementia case register received a standardised evaluation which incorporated a neuropsychological assessment with the Cambridge Assessment for disorders in the elderly (CAMCOG). Operationalised clinical diagnoses were made (consensus criteria for dementia with Lewy bodies, DLB; NINCDS- ADRDA for Alzheimer's disease, AD, NINCDS AIRENS for vascular dementia, VaD). Two-hundred and twenty-eight patients were studied (DLB 54, AD102, VaD 72). DLB patients had significantly better performance on recent memory than AD patients, but more impaired visuospatial praxis. DLB patients also had significantly better recent memory than those with VaD. Optimal cut-off points for the recent memory:praxis ratio achieved good discrimination between DLB and both other dementias.

Entities:  

Mesh:

Year:  1999        PMID: 10026383     DOI: 10.1159/000017109

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  9 in total

1.  Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease.

Authors:  T A Ala; L F Hughes; G A Kyrouac; M W Ghobrial; R J Elble
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

Review 2.  Dementia with Lewy bodies. Review of diagnosis and pharmacologic management.

Authors:  Christopher Frank
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

3.  Visual association test to detect early dementia of the Alzheimer type.

Authors:  J Lindeboom; B Schmand; L Tulner; G Walstra; C Jonker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

4.  Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease.

Authors:  D Aarsland; I Litvan; D Salmon; D Galasko; T Wentzel-Larsen; J P Larsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 5.  Diagnosis and treatment of dementia: 2. Diagnosis.

Authors:  Howard H Feldman; Claudia Jacova; Alain Robillard; Angeles Garcia; Tiffany Chow; Michael Borrie; Hyman M Schipper; Mervin Blair; Andrew Kertesz; Howard Chertkow
Journal:  CMAJ       Date:  2008-03-25       Impact factor: 8.262

6.  Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A Comparison of Prodromal and Dementia Stages.

Authors:  Frederic Blanc; Sean J Colloby; Nathalie Philippi; Xavier de Pétigny; Barbara Jung; Catherine Demuynck; Clélie Phillipps; Pierre Anthony; Alan Thomas; Fabrice Bing; Julien Lamy; Catherine Martin-Hunyadi; John T O'Brien; Benjamin Cretin; Ian McKeith; Jean-Paul Armspach; John-Paul Taylor
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

7.  Insular atrophy at the prodromal stage of dementia with Lewy bodies: a VBM DARTEL study.

Authors:  Daniel Roquet; Vincent Noblet; Pierre Anthony; Nathalie Philippi; Catherine Demuynck; Benjamin Cretin; Catherine Martin-Hunyadi; Paulo Loureiro de Sousa; Frédéric Blanc
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

8.  Parkinson's Disease Dementia and Dementia with Lewy Bodies Have Similar Neuropsychological Profiles.

Authors:  Georgina M Aldridge; Allison Birnschein; Natalie L Denburg; Nandakumar S Narayanan
Journal:  Front Neurol       Date:  2018-03-12       Impact factor: 4.003

9.  The revised Addenbrooke's Cognitive Examination can facilitate differentiation of dementia with Lewy bodies from Alzheimer's disease.

Authors:  Maria Angeles Prats-Sedano; George Savulich; Ajenthan Surendranathan; Paul C Donaghy; Alan J Thomas; James B Rowe; Li Su; John T O'Brien
Journal:  Int J Geriatr Psychiatry       Date:  2020-12-14       Impact factor: 3.850

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.